Close

BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML

Go back to BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML

BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference

September 8, 2016 7:00 AM EDT

TEL AVIV, Israel, September 8, 2016 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML) were presented yesterday evening at the 4th Annual Meeting of the Society of Hematologic Oncology (SOHO), being held September 7-10, 2016, in Houston, Texas.

BL-8040, BioLineRx's lead oncology platform, is a short cyclic peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis,... More